Penn Capital Management Co. Inc. grew its position in shares of Elanco Animal Health (NASDAQ:ELAN) by 19.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,789 shares of the company’s stock after purchasing an additional 9,041 shares during the period. Penn Capital Management Co. Inc.’s holdings in Elanco Animal Health were worth $5,292,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of ELAN. Morgan Stanley purchased a new position in shares of Elanco Animal Health during the third quarter valued at about $314,448,000. Janus Henderson Group PLC grew its position in Elanco Animal Health by 377.9% in the first quarter. Janus Henderson Group PLC now owns 8,278,745 shares of the company’s stock worth $265,499,000 after acquiring an additional 6,546,483 shares in the last quarter. Amundi Pioneer Asset Management Inc. grew its position in Elanco Animal Health by 115,239.6% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 5,766,978 shares of the company’s stock worth $181,833,000 after acquiring an additional 5,761,978 shares in the last quarter. Vanguard Group Inc. purchased a new position in Elanco Animal Health in the third quarter worth about $176,182,000. Finally, Sound Shore Management Inc. CT purchased a new position in Elanco Animal Health in the first quarter worth about $115,600,000.
Shares of NASDAQ ELAN opened at $33.34 on Thursday. Elanco Animal Health has a 1 year low of $28.00 and a 1 year high of $37.61.
Elanco Animal Health (NASDAQ:ELAN) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.03. The firm had revenue of $731.10 million during the quarter, compared to the consensus estimate of $743.40 million. The firm’s revenue for the quarter was down .7% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 EPS.
Several research firms recently commented on ELAN. Zacks Investment Research lowered Elanco Animal Health from a “buy” rating to a “hold” rating in a research report on Tuesday, March 5th. BMO Capital Markets lifted their price target on Elanco Animal Health from $32.00 to $35.00 and gave the stock a “market perform” rating in a research report on Friday, May 10th. Bank of America upgraded Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $30.95 price target for the company in a research report on Monday, March 18th. Morgan Stanley began coverage on Elanco Animal Health in a research report on Wednesday, March 13th. They issued an “equal weight” rating and a $34.00 price target for the company. Finally, UBS Group began coverage on Elanco Animal Health in a research report on Wednesday, March 20th. They issued a “sell” rating and a $28.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $33.47.
In other news, Director R David Hoover acquired 20,000 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was acquired at an average price of $31.43 per share, with a total value of $628,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John P. Bilbrey acquired 7,750 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was purchased at an average cost of $32.39 per share, with a total value of $251,022.50. The disclosure for this purchase can be found here.
TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2019/05/16/elanco-animal-health-elan-shares-bought-by-penn-capital-management-co-inc.html.
Elanco Animal Health Company Profile
There is no company description available for Elanco Animal Health Inc
Read More: What are earnings reports?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.